AEON Biopharma, Inc.

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

0.28 on 9 Oct 2026

1 buy0 sales at will0 planned sales

Fiscal year 2025, ended 31 Dec 2025, as filed

Net income

$39.22M

Free cash flow

$17.31M

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
19 Aug 2026	LYNCH TIMOTHY P 10% owner	Bought	$243.46K	21.5%
21 May 2025	FISCHER JOST Director	Bought	$29.25K	29.0%
20 May 2025	FISCHER JOST Director	Bought	$30.36K	40.9%
19 May 2025	FISCHER JOST Director	Bought	$24.94K	51.7%
11 Aug 2023	Strathspey Crown Holdings Group, LLC 10% owner	Sold at will	$73.80M	78.4%

43out of 100

Profitability 50

Financial strength 10

Growth n/a

Insiders 75

Strongest on insiders (75), weakest on financial strength (10). A score of the business, not of the price.

Last 12 months

Only here

Bought

$243.46K

1 buy, 1 buyer

Sold

$0.00

0 sales

Planned sales

n/a

under a 10b5-1 plan